Juvenile myelomonocytic leukemia
Revision as of 14:54, 31 May 2023 by Warner-admin (talk | contribs) (Text replacement - "(NCT[0-9]{8})" to "[https://clinicaltrials.gov/ct2/show/$1 Clinical Trial Registry]")
1 regimens on this page
1 variants on this page
|
First-line therapy
Azacitidine monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Niemeyer et al. 2021 (AZA-JMML-001) | 2015-2017 | Phase 2, <20 pts (RT) |
References
- AZA-JMML-001: Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. link to original article link to PMC article PubMed Clinical Trial Registry